AdTech Vendor · Publisher & Media Owner · vs · Advertiser / Brand
Doceree vs Humana
Structured technology and market comparison · 2026
Direct Feature Comparison
Doceree · vs · HumanaHealthcare adtech platform for pharma, publishers and HCP targeting.
US health insurer focused on Medicare and integrated care.
Analyze all overlapping signals and tech stacks for Doceree and Humana
Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.
Comparison Analysis
What is the main difference between Doceree and Humana?
When comparing Doceree and Humana, both platforms operate within the AdTech Vendor · Publisher & Media Owner and Advertiser / Brand ecosystem. Doceree is positioned as Healthcare adtech platform for pharma, publishers and HCP targeting, whereas Humana focuses on US health insurer focused on Medicare and integrated care. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.
What are the top alternatives to Doceree and Humana?
When evaluating Doceree and Humana, enterprise buyers also consider other platforms in AdTech Vendor · Publisher & Media Owner and Advertiser / Brand. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.
How do the corporate scale, structure, and headquarters of Doceree and Humana compare?
Doceree is headquartered in US (founded in 2020) with 201–500 employees. Humana is based in US (founded in 1961) with >5,000 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.
Market Signals
Recent Market Signals & Activity: Doceree vs Humana
Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.
Doceree
Recent Signals
- ·Doceree
Highlights of the Fierce Pharma Week 2026
The night before Fierce Pharma Week 2026, Doceree launched its Intent-Powered HCP Suite with...
Humana
Recent Signals
- ·SEC APIfinancials
8-K Financial Filing Analysis for Humana (2026-10-13)
On October 13, 2026, Humana Inc. announced a new joint venture arrangement with funds managed by HPS Investment Partners, a subsidiary of BlackRock, Inc., to manage and operate its CenterWell Senior Primary Care clinic network. This arrangement replaces CenterWell's existing joint venture with Welsh, Carson, Anderson & Stowe (WCAS), with BlackRock acquiring WCAS's equity stake under modified terms. Notably, the new JV eliminates the previous put option held by WCAS, resulting in an expected significant reduction in balance sheet liabilities and a lower overall cost of capital. Concurrently, Humana reaffirmed its FY 2026 Adjusted EPS guidance of at least $9.00.
- BlackRock subsidiary HPS Investment Partners acquired WCAS's equity stake in CenterWell Senior Primary Care clinics under a restructured joint venture eliminating previous put option liabilities.
- CenterWell secures the option to purchase clinics starting in 2028, with BlackRock holding exit rights via a sale process by end-2033 if clinics remain unacquired.
- Humana reaffirmed its full-year 2026 Adjusted EPS guidance of at least $9.00 per common share.
- ·SEC APIfinancials
8-K Financial Filing Analysis for Humana (2026-10-09)
Humana Inc. announced that it has exceeded its goal of Top Quartile results for the 2027 Medicare Advantage (MA) Star Ratings (Bonus Year 2028), based on final data released by the Centers for Medicare and Medicaid Services (CMS) on October 8, 2026. Top Quartile performance is defined as Stars revenue per member per month (PMPM) at least 10% above the peer group median. While anticipating that a portion of the 2028 bonus outperformance will be one-time in nature, Humana expects to utilize the resulting financial benefit for one-time investments and capital returns to shareholders. Concurrently, the company reaffirmed its full-year 2026 Adjusted EPS guidance of at least $9.00 and announced a virtual investor update scheduled for December 10, 2026.
- Exceeded the Top Quartile target for 2027 CMS Medicare Advantage Star Ratings (Bonus Year 2028), defined as Stars revenue PMPM 10% above the peer group median.
- Reaffirmed full-year 2026 Adjusted EPS guidance of at least $9.00 per share.
- Scheduled a virtual investor update for December 10, 2026, to review progress against the multi-year earnings framework through 2028.
- ·Humana
Humana Maintains Affordable Medicare Advantage Plans and Expands Specialized Care Options for 2027
Press Release | 10/01/2026 Humana Maintains Affordable Medicare Advantage Plans and Expands Specialized Care Options for 2027
Compare their exact ecosystem overlaps.
Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners Doceree and Humana share across the market ecosystem.
Unlock full capability matrix, client overlaps & technology stacks